NCT05098028View on ClinicalTrials.gov

Pharmacokinetics and Pharmacodynamics of Rifaximin Novel Formulations in Patients With Sickle Cell Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

March 22, 2022

Primary Completion Date

September 4, 2023

Study Completion Date

September 4, 2023

Conditions
Sickle Cell Disease
Interventions
DRUG

Low Dose Rifaximin ER

Low Dose Rifaximin Extended Release Twice Daily

DRUG

Low Dose Rifaximin DER

Low Dose Rifaximin Delayed Extended Release Twice Daily

DRUG

High Dose Rifaximin ER

High Dose Rifaximin Extended Release Twice Daily

DRUG

High Dose Rifaximin DER

High Dose Rifaximin Delayed Extended Release Twice Daily

DRUG

Placebo

Placebo Twice Daily

Trial Locations (8)

13210

Bausch Site 101, Syracuse

27834

Bausch Site 102, Greenville

30100

Bausch Site 501, Eldoret

30329

Bausch Site 104, Atlanta

40100

Bausch Site 502, Kisumu

80220

Bausch Site 103, Denver

92868

Bausch Site 105, Orange

H2X 3E4

Bausch Site 201, Montreal

All Listed Sponsors
lead

Bausch Health Americas, Inc.

INDUSTRY